Key result
Radioiodination of AAVrh.10 capsids enables in vivo murine brain PET tracking for ~8 days.
Why the study?
Does radiolabeling adeno-associated virus with iodine-124 allow in vivo non-invasive tracking in a murine model?
Does radiolabeling adeno-associated virus with iodine-124 allow in vivo non-invasive tracking in a murine model?
Absolute Event Rate: 1.83% vs 1.47%
p-value: p=0.02
Capsid radioiodination of AAV vectors enables non-invasive, whole-body in vivo tracking of vector distribution using PET imaging.
Supports PET tracking of AAV in murine brain; hypothesis-generating for vector biodistribution before clinical translation.
Viral vector mediated gene therapy has become commonplace in clinical trials for a wide range of inherited disorders. Successful gene transfer depends on a number of factors, of which tissue tropism is among the most important. To date, definitive mapping of the spatial and temporal distribution of viral vectors in vivo has generally required postmortem examination of tissue. Here we present two methods for radiolabeling adeno-associated virus (AAV), one of the most commonly used viral vectors for gene therapy trials, and demonstrate their potential usefulness in the development of surrogate markers for vector delivery during the first week after administration. Specifically, we labeled adeno-associated virus serotype 10 expressing the coding sequences for the CLN2 gene implicated in late infantile neuronal ceroid lipofuscinosis with iodine-124. Using direct (Iodogen) and indirect (modified Bolton-Hunter) methods, we observed the vector in the murine brain for up to one week using positron emission tomography. Capsid radioiodination of viral vectors enables non-invasive, whole body, in vivo evaluation of spatial and temporal vector distribution that should inform methods for efficacious gene therapy over a broad range of applications.
No takes yet. Share an insight, caveat, or question.
Kothari et al. (2017) studied Late infantile neuronal ceroid lipofuscinosis (LINCL) gene therapy tracking (n=31). I-124 labeled AAVrh.10CLN2 (Iodogen method) vs. I-124 labeled AAVrh.10CLN2 (modified Bolton-Hunter method) was evaluated on Biological half-life (Tbio) in days (p=0.02). Radioiodination of AAVrh.10 capsids using Iodogen or modified Bolton-Hunter methods enabled in vivo PET tracking in the murine brain for up to eight days, with biological half-lives of 1.83 and 1.47 days, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: